PMID- 38010876
OWN - NLM
STAT- MEDLINE
DCOM- 20231129
LR  - 20231129
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 28
IP  - 1
DP  - 2023 Dec
TI  - Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a 
      systematic literature review and meta-analysis.
PG  - 2284047
LID - 10.1080/16078454.2023.2284047 [doi]
AB  - OBJECTIVES: The role of subcutaneous (SC) rituximab in the efficacy and safety to 
      non-Hodgkin lymphoma (NHL) is not clear enough. The purpose of this study was to 
      conduct a systematic review and meta-analysis, to assess the efficacy and safety 
      of subcutaneous rituximab to NHL. METHOD: A full-scale search was carried out 
      based on the set search terms in PubMed, Web of Science, Embase and Cochrane 
      CENTRAL until 12 October 2022 to identify relevant studies of subcutaneous 
      rituximab for NHL. The efficacy and safety outcomes included complete response 
      (CR) plus unconfirmed complete response (CRu), adverse events (AEs), grade >/=3 
      AEs, serious adverse events (SAEs), administration-related reactions (ARRs), 
      adverse reaction rates. RESULTS: From a total of 758 studies, 9 trials were 
      eligible. The CR/CRu of patients with NHL receiving SC rituximab was 57%, 55% for 
      Diffuse large B-cell lymphoma (DLBCL) and 54% for Follicular lymphoma (FL). The 
      meta-analysis performed on safety demonstrated that AEs of NHL patients with SC 
      rituximab was 85%, grade >/=3 AEs was 38%, SAE was 27% and ARR was 33%. The result 
      also showed that SC rituximab had a high risk of neutropenia and nausea. 
      CONCLUSION: For NHL patients, there is no significant difference in the efficacy 
      between subcutaneous rituximab and conventional therapy, while subcutaneous 
      injection can shorten exposure time in the hospital and reduce the risk of 
      infection.
FAU - Si, Tianyu
AU  - Si T
AUID- ORCID: 0000-0003-3945-7481
AD  - Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      People's Republic of China.
FAU - Ma, Xiaolin
AU  - Ma X
AD  - Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      People's Republic of China.
FAU - Zhu, Wenwei
AU  - Zhu W
AD  - Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      People's Republic of China.
FAU - Zhou, Yongming
AU  - Zhou Y
AD  - Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20231127
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Humans
MH  - Rituximab/adverse effects
MH  - *Lymphoma, Non-Hodgkin/drug therapy/etiology
MH  - Treatment Outcome
MH  - *Lymphoma, Follicular/chemically induced/drug therapy
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
OTO - NOTNLM
OT  - Diffuse large B-cell lymphoma
OT  - Follicular lymphoma
OT  - Non-Hodgkin lymphoma
OT  - efficacy
OT  - meta-analysis
OT  - rituximab
OT  - safety
OT  - subcutaneous
EDAT- 2023/11/27 18:43
MHDA- 2023/11/29 06:43
CRDT- 2023/11/27 12:22
PHST- 2023/11/29 06:43 [medline]
PHST- 2023/11/27 18:43 [pubmed]
PHST- 2023/11/27 12:22 [entrez]
AID - 10.1080/16078454.2023.2284047 [doi]
PST - ppublish
SO  - Hematology. 2023 Dec;28(1):2284047. doi: 10.1080/16078454.2023.2284047. Epub 2023 
      Nov 27.